NeuroNEXT

The new network SOPs have been posted to the website as of March 20, 2024, which will be effective as of April 8, 2024.

Recently there were some revisions to the URGenT ROAs made.  OTA-24-011 and OTA-24-012 replaced OTA-24-002 and OTA-24-003, respectively.  The revisions were minor and mainly included updating some language in accordance with NIH policy, and inclusion of references for CDEs. The new ROAs can be found here: Research Opportunity Announcements | National Institute of Neurological Disorders and…

We are pleased to announce the continuation of the NINDS Clinical Trials Methodology Course (CTMC). We are currently accepting applications for the 2024 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective,…

The Annual SCT Meeting registration is now open.  This year it will be hosted in Boston, MA on 5/19- 5/22.  Please see the attached link for more details. https://acrobat.adobe.com/link/track?uri=urn:aaid:scds:US:79c97166-8b69-3846-937f-ee224531d376

NOI for 2 new ROAs will be issued for NeuroNEXT Clinical Trials: Stage 1 Preliminary Application and Stage 2 Protocol Application will replace the current Notice of Funding Opportunity ‘NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) PAR-21-223’ expiring on March 06, 2024. NOI: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-045.html

The ROAs for the Gene Therapy Consortium were published on December 4, 2023.  Please find the links below.  The submissions will be accepted starting on December 28, 2023 and the submission deadline is rolling. https://www.ninds.nih.gov/sites/default/files/documents/URGenT%20CT%20NN%20ROA%20Stage1_clean_508C.pdf https://www.ninds.nih.gov/sites/default/files/documents/URGenT%20CT%20NN%20ROA%20Stage2_clean_508C.pdf

Dr. Francis Rossignol of hte NIH National Human Genome Research Institute (NHBRI) will present as part of theGNEM Symposium Speaker Series presented by the Neuromuscular Disease Foundation. His talk, entitled “ManNAc As A Potential Therapy for GNE Myopathy – Advances and Future Directions” will include discussion of NN109. This talk is free of charge and available virtually. More information…

The RFAs for the network renewal were published on September 20, 2022. Please find links below. The deadline for grant submissions is November 21, 2022. Please note that there has been a notice of correction published related to the site RFA: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-028.html

NN106 CYTO-C Prospective biomarker study results have been published in Neurooncology Advances.  

Results of the NN103 study were cited in NeurologyLive.